


What is claimed is:

1. A compound for modulating c-Kit activity according to Formula I,



II

or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, wherein,

ring A is a five- to fourteen-membered heteroaryl;

each R^1 is independently selected from -H, halogen, trihalomethyl, -CN, -NO₂, -OR⁴, -N(R⁴)R⁴, -S(O)₀₋₂R⁴, -SO₂N(R⁴)R⁴, -CO₂R⁴, -C(=O)N(R⁴)R⁴, -C(=NR⁵)N(R⁴)R⁴, -C(=NR⁵)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, -NCO₂R⁴, -C(=O)R⁴, optionally substituted alkoxy, optionally substituted C₁₋₆alkyl, optionally substituted aryl, optionally substituted aryl C₁₋₆alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C₁₋₆alkyl;

two adjacent of R^1 , together with the annular atoms to which they are attached, can form a five- to six-membered ring containing up to two heteroatoms and optionally substituted with up to three of R¹⁰;

L^1 is selected from a single bond, an optionally substituted C₁₋₂alkylene, -O-, -CH₂O-, -N(R⁷)-, -C(=O)N(R⁷)-, -SO₂N(R⁷)-, -CH₂N(R⁷)-, and -S(O)₀₋₂-;

ring B is a five- to ten-membered aryl or a five- to ten-membered heterocyclyl;

each R^2 is independently selected from -H, halogen, trihalomethyl, -CN, -NO₂, -OR⁴, -N(R⁴)R⁴, -S(O)₀₋₂R⁴, -SO₂N(R⁴)R⁴, -CO₂R⁴, -C(=O)N(R⁴)R⁴, -C(=NR⁵)N(R⁴)R⁴, -C(=NR⁵)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, -NCO₂R⁴, -C(=O)R⁴, optionally substituted alkoxy, optionally substituted C₁₋₆alkyl, optionally substituted aryl, optionally substituted aryl C₁₋₆alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C₁₋₆alkyl;

two adjacent of R^2 , together with the annular atoms to which they are attached, can form a five- to six-membered ring containing up to two heteroatoms and optionally substituted with up to three of R¹⁵;

L^2 is a selected from C_4 alkylene, C_4 alkylidene, C_4 alkylidyne, $-X(CH_2)_2O-$, $-X(CH_2)_2N(R^7)-$, $-XCH_2SO_2N(R^7)-$, $-XN(R^7)C(=O)N(R^7)-$, $-XCH_2C(=O)N(R^7)-$, $-(CH_2)_3X-$, $-XN(R^7)SO_2N(R^7)-$, $-XCH_2N(R^7)SO_2-$, $-CH_2X(CH_2)_2-$, $-CH=CHC(=O)N(R^7)-$, $-CH=CHSO_2N(R^7)-$, $-XCH_2N(R^7)C(=O)-$, $-M-M-$, $-CH_2N(R^7)C(=O)O-$, and $-CH_2OC(=O)N(R^7)-$; wherein X is selected from $-CH_2-$, $-O-$, $-N(R^7)-$, $-C(=O)-$, and $-S(O)_{0-2}-$; M is selected from $-C(=O)N(R^7)-$ and $-SO_2N(R^7)-$; and any C-H of L^2 is optionally $C-R^{20}$;

ring C is either a five- to ten-membered aryl or a five- to ten-membered heteroaryl;

each R^3 is independently selected from -H, halogen, trihalomethyl, $-CN$, $-NO_2$, $-OR^4$, $-N(R^4)R^4$, $-S(O)_{0-2}R^4$, $-SO_2N(R^4)R^4$, $-CO_2R^4$, $-C(=O)N(R^4)R^4$, $-C(=NR^5)N(R^4)R^4$, $-C(=NR^5)R^4$, $-N(R^4)SO_2R^4$, $-N(R^4)C(O)R^4$, $-NCO_2R^4$, $-C(=O)R^4$, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl; provided R^3 is not a cyclic sulfonamide attached to ring C via the nitrogen of said cyclic sulfonamide;

two adjacent of R^3 , together with the annular atoms to which they are attached, can form a five- to six-membered ring containing up to two heteroatoms and optionally substituted with up to three of R^{25} ;

R^4 is selected from -H, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl;

two of R^4 , when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P;

R^5 is selected from -H, $-CN$, $-NO_2$, $-OR^4$, $-S(O)_{0-2}R^4$, $-CO_2R^4$, optionally substituted C_{1-6} alkyl, optionally substituted C_{1-6} alkenyl, and optionally substituted C_{1-6} alkynyl;

R^7 is selected from -H, optionally substituted C_{1-6} alkyl, $-SO_2N(R^4)R^4$, $-CO_2R^4$, $-C(=O)N(R^4)R^4$, $-C(=NR^5)N(R^4)R^4$, $-C(=NR^5)R^4$, $-C(=O)R^4$, optionally substituted alkoxy, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl; and

each of R^{10} , each of R^{15} , each of R^{20} , and each of R^{25} is independently selected from -H, halogen, trihalomethyl, -CN, -NO₂, -OR⁴, -N(R⁴)R⁴, -S(O)₀₋₂R⁴, -SO₂N(R⁴)R⁴, -CO₂R⁴, -C(=O)N(R⁴)R⁴, -C(=NR⁵)N(R⁴)R⁴, -C(=NR⁵)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, -NCO₂R⁴, -C(=O)R⁴, optionally substituted alkoxy, optionally substituted C₁₋₆alkyl, optionally substituted aryl, optionally substituted aryl C₁₋₆alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C₁₋₆alkyl;

provided:

1) when both ring B and ring C are phenyl:


- a) and the compound comprises ring B-CH₂N(H)C(=O)N(H)-ring C, then L¹ must be a single bond; R³ can not comprise a group of the formula -O(CH₂)₂₋₄-N-piperazine that is *ortho*- to L²; and ring A cannot be a 5-methyl-[1,2,4]-oxadiazol-3-yl radical, a 4H-[1,2,4]-oxadiazol-5-one-3-yl radical, nor a 4'-[2,2';6',2'']terpyridinyl radical;
- b) and L¹ is single bond, then L² cannot comprise -N(H)C(=O)C(=O)N(H)- nor -N(H)C(=Q)C(H)CNC(=O)- (where Q is S or O);
- c) and L¹ is other than single bond, then A cannot be quinolin-2-yl-L¹, quinolin-3-yl-L¹, or quinolin-4-yl-L¹;

2) when ring A is a fused aryl system, then L¹ must be a single bond;

3) when ring B is phenyl, ring C is a C₆₋₁₆carbocyclic, L¹ is a single bond, and the compound comprises -ring B-OCH₂C(=O)N(H)- then ring A cannot be a 2,5-dimethyl-1H-pyrrole-1-yl radical;

4) ring A cannot be a pyrimidin-2-yl radical when L¹ is -N(H)- and ring B is phenyl;

5) when the compound comprises the formula,


















where V is =C(H)- or =N-, and there is a nitrogen of L² bound directly to ring B, then A can not comprise a [1,2,4]-oxadiazol-3-yl radical; and

- 6) the compound is not one of: N-naphthalen-1-yl-2-{{3-(1H-tetrazol-1-yl)phenyl}oxy}acetamide, N-[4-(phenyloxy)phenyl]-2-{{3-(1H-tetrazol-1-yl)phenyl}oxy}acetamide, N-(3,4-dimethylphenyl)-2-{{3-(1H-tetrazol-1-yl)phenyl}oxy}acetamide, N-(2,3-dimethylphenyl)-2-{{3-(1H-tetrazol-1-yl)phenyl}oxy}acetamide, N-(2,4-dimethylphenyl)-2-{{3-(1H-tetrazol-1-yl)phenyl}oxy}acetamide, N-(2,5-dimethylphenyl)-2-{{3-(1H-tetrazol-1-yl)phenyl}oxy}acetamide, N-(3,5-dimethylphenyl)-2-{{3-(1H-tetrazol-1-yl)phenyl}oxy}acetamide, N-(2,6-dimethylphenyl)-2-{{3-(1H-tetrazol-1-yl)phenyl}oxy}acetamide, 2-{{3-(1H-tetrazol-1-yl)phenyl}oxy}-N-(2,4,6-trimethylphenyl)acetamide, N-(2-ethylphenyl)-2-{{3-(1H-tetrazol-1-yl)phenyl}oxy}acetamide, N-(4-ethylphenyl)-2-{{3-(1H-tetrazol-1-yl)phenyl}oxy}acetamide, N-(2,6-diethylphenyl)-2-{{3-(1H-tetrazol-1-yl)phenyl}oxy}acetamide, N-[2-(methyloxy)phenyl]-2-{{3-(1H-tetrazol-1-yl)phenyl}oxy}acetamide, N-[2-(ethyloxy)phenyl]-2-{{3-(1H-tetrazol-1-yl)phenyl}oxy}acetamide, N-[3-(ethyloxy)phenyl]-2-{{3-(1H-tetrazol-1-yl)phenyl}oxy}acetamide, N-[2,4-bis(methyloxy)phenyl]-2-{{3-(1H-tetrazol-1-yl)phenyl}oxy}acetamide, N-[4-(dimethylamino)phenyl]-2-{{3-(1H-tetrazol-1-yl)phenyl}oxy}acetamide, N-(2,3-dichlorophenyl)-2-{{3-(1H-tetrazol-1-yl)phenyl}oxy}acetamide, N-(4-chloro-3-methylphenyl)-2-{{3-(1H-tetrazol-1-yl)phenyl}oxy}acetamide, N-(4-bromophenyl)-2-{{3-(1H-tetrazol-1-yl)phenyl}oxy}acetamide, N-(2-fluorophenyl)-2-{{3-(1H-tetrazol-1-yl)phenyl}oxy}acetamide, N-(4-fluorophenyl)-2-{{3-(1H-tetrazol-1-yl)phenyl}oxy}acetamide, 2-{{3-(1H-tetrazol-1-yl)phenyl}oxy}-N-[2-(trifluoromethyl)phenyl]acetamide, 2-{{3-(1H-tetrazol-1-yl)phenyl}oxy}-N-[3-(trifluoromethyl)phenyl]acetamide, methyl 4-[[{{3-(1H-tetrazol-1-yl)phenyl}oxy}acetyl]amino]benzoate, ethyl 4-[[{{3-(1H-tetrazol-1-yl)phenyl}oxy}acetyl]amino]benzoate, 3-[[{{3-(1H-tetrazol-1-yl)phenyl}oxy}acetyl]amino]benzoic acid, N-[3-(methyloxy)phenyl]-2-{{3-(1H-tetrazol-1-yl)phenyl}oxy}acetamide, N-[4-(methyloxy)phenyl]-2-{{3-(1H-tetrazol-1-yl)phenyl}oxy}acetamide, N-[2-chloro-5-(trifluoromethyl)phenyl]-2-{{3-(1H-tetrazol-1-yl)phenyl}oxy}acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-{{3-(4H-1,2,4-triazol-4-yl)phenyl}oxy} acet-

amide, N-(4-chlorophenyl)-2-[[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(4-aminophenyl)-2-[[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, and N-(4-acetylphenyl)-2-[[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide.

2. The compound according to claim 1, wherein L^1 is a single bond.
3. The compound according to claim 2, wherein ring A contains between one and four annular nitrogens.
4. The compound according to claim 3, wherein ring A is selected from the following:
















wherein each Y is independently either =C(H)- or =N-; and Z is selected from -O-, -S(O)₀₋₂-, and -N(R⁷)-.

5. The compound according to claim 4, wherein ring B is phenylene or pyridylene.
6. The compound according to claim 5, wherein the annular atoms of ring B to which L^1 and L^2 are attached are not contiguous.

7. The compound according to claim 6, wherein L^2 is selected from $-X(CH_2)_2O-$, $-X(CH_2)_2N(R^7)-$, $-CH_2XC(=O)N(R^7)-$, $-XCH_2SO_2N(R^7)-$, $-XN(R^7)C(=O)N(R^7)-$ and $-XCH_2C(=O)N(R^7)-$; wherein X is selected from $-CH_2-$, $-O-$, $-S(O)_{0-2}-$ and $-N(R^7)-$; and any C-H of L^2 is optionally C- R^{20} .

8. The compound according to claim 7, wherein L^2 is selected from $-N(H)N(H)C(=O)N(H)-$, $-CH_2N(H)C(=O)N(H)-$, $-CH_2OC(=O)N(H)-$, and $-XCH_2C(=O)N(H)-$; wherein X is selected from $-O-$, $-S(O)_{0-2}-$, and $-N(R^7)-$; and any C-H of L^2 is optionally C- R^{20} .

9. The compound according to claim 8, wherein ring A is selected from the following:


		
		
		
		
		

wherein each Y is independently either $=C(H)-$ or $=N-$; and Z is selected from $-O-$, $-S-$, and $-N(R^7)-$.

10. The compound according to claim 9, wherein ring C is phenyl or pyridyl.

11. The compound according to claim 10, wherein there exists at least one of R^3 that is halogen.


12. The compound according to claim 10, wherein there exists at least one of R^3 that is trihalomethyl.
13. The compound according to claim 10, wherein there exists at least one of R^3 that is trifluoromethyl.
14. The compound according to claim 13, wherein ring C is a phenyl comprising a trifluoromethyl radical *meta*- to L^2 .
15. The compound according to claim 10, wherein each of R^3 is independently selected from -H, halogen, trihalomethyl, $-OR^4$, $-CO_2R^4$, $-C(=O)R^4$, and optionally substituted C_{1-6} alkyl.
16. A compound for modulating c-Kit activity according to Formula II,



II

or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, wherein,

W is selected from the following:



each of R^{27} independently selected from halogen, trihalomethyl, $-\text{CN}$, $-\text{NO}_2$, $-\text{OR}^{55}$, $-\text{N}(\text{R}^{55})\text{R}^{55}$, $-\text{S}(\text{O})_{0-2}\text{R}^{55}$, $-\text{SO}_2\text{N}(\text{R}^{55})\text{R}^{55}$, $-\text{CO}_2\text{R}^{55}$, $-\text{C}(=\text{O})\text{N}(\text{R}^{55})\text{R}^{55}$, $-\text{C}(=\text{NR}^{50})\text{N}(\text{R}^{55})\text{R}^{55}$, $-\text{C}(=\text{NR}^{50})\text{R}^{55}$, $-\text{N}(\text{R}^{55})\text{SO}_2\text{R}^{55}$, $-\text{N}(\text{R}^{55})\text{C}(\text{O})\text{R}^{55}$, $-\text{NCO}_2\text{R}^{55}$, $-\text{C}(=\text{O})\text{R}^{55}$, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl;

each Y is independently either $=\text{C}(\text{H})-$ or $=\text{N}-$;

Z is selected from $-\text{O}-$, $-\text{S}(\text{O})_{0-2}-$, and $-\text{N}(\text{R}^7)-$

E and G are each independently selected from $-\text{O}-$, $-\text{S}(\text{O})_{0-2}-$, $-\text{C}(\text{R}^{31})\text{R}^{32}-$, and $-\text{N}(\text{R}^{33})-$;

J_1 and J_2 are each independently $=\text{C}(\text{H})-$ or $=\text{N}-$;

each of R^{26} and R^{30} is independently selected from $-\text{H}$, halogen, trihalomethyl, $-\text{CN}$, $-\text{NO}_2$, $-\text{OR}^{40}$, $-\text{N}(\text{R}^{40})\text{R}^{40}$, $-\text{S}(\text{O})_{0-2}\text{R}^{40}$, $-\text{SO}_2\text{N}(\text{R}^{40})\text{R}^{40}$, $-\text{CO}_2\text{R}^{40}$, $-\text{C}(=\text{O})\text{N}(\text{R}^{40})\text{R}^{40}$, $-\text{C}(=\text{NR}^{50})\text{N}(\text{R}^{40})\text{R}^{40}$, $-\text{C}(=\text{NR}^{50})\text{R}^{40}$, $-\text{N}(\text{R}^{40})\text{SO}_2\text{R}^{40}$, $-\text{N}(\text{R}^{40})\text{C}(\text{O})\text{R}^{40}$, $-\text{NCO}_2\text{R}^{40}$, $-\text{C}(=\text{O})\text{R}^{40}$, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl;

two adjacent of R^{26} or two adjacent of R^{30} , together with the annular atoms to which they are attached, can form a five- to six-membered ring containing up to two heteroatoms and optionally substituted with up to three of R^{35} ;

R^{31} and R^{32} are each independently selected from $-\text{H}$, halogen, trihalomethyl, $-\text{CN}$, $-\text{NO}_2$, $-\text{OR}^{40}$, $-\text{N}(\text{R}^{40})\text{R}^{40}$, $-\text{S}(\text{O})_{0-2}\text{R}^{40}$, $-\text{SO}_2\text{N}(\text{R}^{40})\text{R}^{40}$, $-\text{CO}_2\text{R}^{40}$, $-\text{C}(=\text{O})\text{N}(\text{R}^{40})\text{R}^{40}$, $-\text{C}(=\text{NR}^{50})\text{N}(\text{R}^{40})\text{R}^{40}$, $-\text{C}(=\text{NR}^{50})\text{R}^{40}$, $-\text{N}(\text{R}^{40})\text{SO}_2\text{R}^{40}$, $-\text{N}(\text{R}^{40})\text{C}(\text{O})\text{R}^{40}$, $-\text{NCO}_2\text{R}^{40}$, $-\text{C}(=\text{O})\text{R}^{40}$, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl;

R^{33} is selected from $-\text{H}$, optionally substituted lower alkyl, $-\text{SO}_2\text{N}(\text{R}^{40})\text{R}^{40}$, $-\text{CO}_2\text{R}^{40}$, $-\text{C}(=\text{O})\text{N}(\text{R}^{40})\text{R}^{40}$, $-\text{C}(=\text{NR}^{50})\text{N}(\text{R}^{40})\text{R}^{40}$, $-\text{C}(=\text{NR}^{50})\text{R}^{40}$, $-\text{C}(=\text{O})\text{R}^{40}$, optionally

substituted alkoxy, optionally substituted C₁₋₆alkyl, optionally substituted aryl, optionally substituted aryl C₁₋₆alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C₁₋₆alkyl;

R⁴⁰ is selected from -H, optionally substituted alkoxy, optionally substituted C₁₋₆alkyl, optionally substituted aryl, optionally substituted aryl C₁₋₆alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C₁₋₆alkyl;

two of R⁴⁰, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P;

R⁵⁰ is selected from -H, -CN, -NO₂, -OR⁴⁰, -S(O)₀₋₂R⁴⁰, -CO₂R⁴⁰, optionally substituted C₁₋₆alkyl, optionally substituted C₁₋₆alkenyl, and optionally substituted C₁₋₆alkynyl;

R⁵⁵ is selected from -H, optionally substituted C₁₋₆alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C₁₋₆alkyl; and

two of R⁵⁵, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P.


17. The compound according to claim 16, wherein the annular carbons of ring B to which W and E are attached are not contiguous.

18. The compound according to claim 17, wherein R³⁰ is selected from -H, halogen, trihalomethyl, -OR⁴⁰, -N(R⁴⁰)R⁴⁰, -CO₂R⁴⁰, -C(=O)R⁴⁰, optionally substituted alkoxy, optionally substituted C₁₋₆alkyl, optionally substituted aryl, optionally substituted aryl C₁₋₆alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C₁₋₆alkyl.

19. The compound according to claim 18, wherein there exists at least one of R³⁰ that is trihalomethyl.

20. The compound according to claim 18, wherein there exists at least one of R³⁰ that is trifluoromethyl.

21. The compound according to claim 18, according to formula III.



III

22. The compound according to claim 21, wherein W is selected from the following:

and R^{27} is defined as above.

23. The compound according to claim 22, wherein E is selected from -O-, $-S(O)_{0-2}$, and -NH-; and G is $-CH_2-$.

24. The compound according to claim 22, wherein E is either $-CH_2-$ or -NH-; and G is selected from -O-, -S-, and -NH-.

25. The compound according to either claim 23 or claim 24, wherein each of R^3 is independently selected from -H, halogen, trihalomethyl, $-OR^4$, $-CO_2R^4$, $-C(=O)R^4$, and optionally substituted C_{1-6} alkyl.

26. The compound according to claim 25, wherein at least one of R³⁰ is a trifluoromethyl radical *meta*- to -E-G-C(=O)N(H)-.

27. The compound according to either claim 1 or claim 16, selected from Table 3:

Table 3

Entry	Name	Structure
1	N-[5-chloro-2-(methyloxy)phenyl]-2-[[3-(1H-tetrazol-1-yl)phenyl]oxy]acetamide	
2	N-phenyl-2-[[3-(1H-tetrazol-1-yl)phenyl]oxy]acetamide	
3	N-(2-methylphenyl)-2-[[3-(1H-tetrazol-1-yl)phenyl]oxy]acetamide	
4	N-(2-chlorophenyl)-2-[[3-(1H-tetrazol-1-yl)phenyl]oxy]acetamide	
5	N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[[3-(1H-tetrazol-1-yl)phenyl]oxy]acetamide	
6	ethyl 2-[[[3-(1H-tetrazol-1-yl)phenyl]oxy]acetyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate	

Table 3

Entry	Name	Structure
7	N-(3-chloro-2-methylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	
8	N-(3-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	
9	N-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[3-(2H-tetrazol-5-yl)phenyl]oxy}acetamide	
10	N-(4-chloro-2-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	
11	N-(4-bromo-3-methylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	
12	N-(4-morpholin-4-ylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	
13	N-[4-fluoro-3-(trifluoromethyl)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	

Table 3

Entry	Name	Structure
14	N-[4-bromo-3-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide	
15	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[4-(1H-tetrazol-1-yl)phenyl]oxy} acetamide	
16	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1-yl)phenyl]oxy} propanamide	
17	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(5-methyl-1H-tetrazol-1-yl)phenyl]oxy} acetamide	
18	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[2-methyl-5-(1H-tetrazol-1-yl)phenyl]oxy} acetamide	
19	N-(4-chlorophenyl)-N-methyl-2- {[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide	
20	N-[4-chloro-2-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide	

Table 3

Entry	Name	Structure
21	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(2,5-dioxopyrrolidin-1-yl)phenyl]oxy} acetamide	
22	(2E)-N-[4-chloro-3-(trifluoromethyl)phenyl]-3-[3-(1H-tetrazol-1-yl)phenyl]prop-2-enamide	
23	N-[4-fluoro-3-(trifluoromethyl)phenyl]-2- {[4-(1H-tetrazol-1-yl)phenyl]oxy} acetamide	
24	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(2-methyl-2H-tetrazol-5-yl)phenyl]oxy} acetamide	
25	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[2,4-dichloro-5-(1H-tetrazol-1-yl)phenyl]oxy} acetamide	
26	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1-yl)phenyl]thio} acetamide	
27	N-[4-chloro-3-(trifluoromethyl)phenyl]- N-2-~[3-(1H-tetrazol-1-yl)phenyl]glycinamide	

Table 3

Entry	Name	Structure
28	N-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[2-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	
29	methyl 1-{3-[(2-{[4-chloro-3-(trifluoromethyl)phenyl]amino}-2-oxoethyl)oxy]phenyl}-1H-1,2,3-triazole-4-carboxylate	
30	1,1-dimethylethyl {4-[(3-(1H-tetrazol-1-yl)phenyl]oxy}acetyl]amino]phenyl}carbamate	
31	1,1-dimethylethyl {4-[(4-(1H-tetrazol-1-yl)phenyl]oxy}acetyl]amino]phenyl}carbamate	
32	N-{4-[(1-ethylpiperidin-4-yl)amino]phenyl}-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	
33	N-{4-[(1-ethylpiperidin-3-yl)amino]phenyl}-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	
34	N-(4-aminophenyl)-2-{[4-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	

Table 3

Entry	Name	Structure
35	N-{4-[(1-ethylpiperidin-4-yl)amino]phenyl}-2-{[4-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	
36	N-{4-[(1-ethylpiperidin-3-yl)amino]phenyl}-2-{[4-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	
37	N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[(3-pyridin-4-ylphenyl)oxy]acetamide	
38	N-[4-chloro-3-(trifluoromethyl)phenyl]-N~2~-methyl-N~2~-[3-(1H-tetrazol-1-yl)phenyl]glycinamide	
39	N-1,3-benzothiazol-2-yl-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	
40	N-quinolin-8-yl-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	
41	N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	

Table 3

Entry	Name	Structure
42	N-isoquinolin-5-yl-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	
43	N-{3-[(phenylmethyl)oxy]phenyl}-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	
44	N-[5-methyl-2-(methyloxy)phenyl]-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	
45	N-[2,5-bis(methyloxy)phenyl]-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	
46	N-(6-fluoro-1,3-benzothiazol-2-yl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	
47	methyl 3-(((3-(1H-tetrazol-1-yl)phenyl)oxy)acetyl)amino]benzoate	
48	5-chloro-2-(((3-(1H-tetrazol-1-yl)phenyl)oxy)acetyl)amino]benzamide	

Table 3

Entry	Name	Structure
49	N-[5-chloro-2,4-bis(methoxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	
50	N-[2-(phenyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	
51	N-[3-(aminosulfonyl)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	
52	N-[2-(methyloxy)-5-(trifluoromethyl)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	
53	N-(4-{[(4-methylphenyl)sulfonyl]amino}phenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	
54	N-(5-phenyl-1H-pyrazol-3-yl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	
55	N-1,3-benzothiazol-2-yl-2-{[4-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	

Table 3

Entry	Name	Structure
56	N-quinolin-8-yl-2-{{[4-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	
57	1,1-dimethylethyl 2-{3-[(2-{[4-chloro-3-(trifluoromethyl)phenyl]amino}-2-oxoethyl)oxy]phenyl}-1H-pyrrole-1-carboxylate	
58	N-[4-chloro-3-(trifluoromethyl)phenyl]-2-{{[3-(1H-pyrrol-2-yl)phenyl]oxy}acetamide	
59	N-[4-chloro-3-(trifluoromethyl)phenyl]-2-{{[3-(1H-pyrimidin-5-yl)phenyl]oxy}acetamide	
60	N-[4-chloro-3-(trifluoromethyl)phenyl]-2-{{[3-(1H-1,2,3-triazol-1-yl)phenyl]oxy}acetamide	
61	4-chloro-N-(2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}ethyl}-3-(trifluoromethyl)aniline	
62	N-[4-chloro-3-(trifluoromethyl)phenyl]-N-(2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}ethyl})formamide	

Table 3

Entry	Name	Structure
63	N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[(3-pyridin-3-ylphenyl)oxy]acetamide	
64	N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[(3-furan-3-ylphenyl)oxy]acetamide	
65	(2E)-N-[4-fluoro-3-(trifluoromethyl)phenyl]-3-[3-(1H-tetrazol-1-yl)phenyl]prop-2-enamide	
66	N-[4-fluoro-3-(trifluoromethyl)phenyl]-3-[3-(1H-tetrazol-1-yl)phenyl]propanamide	
67	N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[[6-(1H-tetrazol-1-yl)pyrimidin-4-yl]oxy]acetamide	
68	N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[[3-(3,5-dimethylisoxazol-4-yl)phenyl]oxy]acetamide	
69	N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[(3-quinolin-7-ylphenyl)oxy]acetamide	

Table 3

Entry	Name	Structure
70	N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[(3-furan-2-ylphenyl)oxy]acetamide	
71	N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenyl]hydrazinecarboxamide	
72	N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[(3-dibenzo[b,d]furan-4-ylphenyl)oxy]acetamide	
73	N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[(4-pyrimidin-5-yl)phenyl]oxy]acetamide	
74	N-methyl-N-[4-(methoxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	
75	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-{[3-(1H-tetrazol-1-yl)phenyl]methyl}urea	
76	N-[4-chloro-3-(trifluoromethyl)phenyl]-N-methyl-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	

Table 3

Entry	Name	Structure
77	N-[4-fluoro-3-(trifluoromethyl)phenyl]-N~2~- [3-(1H-tetrazol-1-yl)phenyl]glycinamide	
78	N-[4-fluoro-3-(trifluoromethyl)phenyl]-2- {[3-(pyridin-2-ylamino)phenyl]oxy}acetamide	
79	N-[2-fluoro-5-(trifluoromethyl)phenyl]-2-[3-(1H-tetrazol-1-yl)phenyl]hydrazinecarboxamide	
80	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(4-pyridin-3-ylphenyl)oxy]acetamide	
81	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(3-pyrimidin-5-ylphenyl)methyl]urea	
82	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(4-pyrimidin-5-ylphenyl)methyl]urea	
83	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(4-pyridin-3-ylphenyl)methyl]urea	

Table 3

Entry	Name	Structure
84	[3-(1H-tetrazol-1-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	
85	N-[4-fluoro-3-(trifluoromethyl)phenyl]-2-[(4-pyrimidin-5-ylphenyl)oxy]acetamide	
86	N-2-[4-chloro-3-(trifluoromethyl)phenyl]-N-[3-(1H-tetrazol-1-yl)phenyl]glycinamide	
87	2-{[4-chloro-3-(trifluoromethyl)phenyl]oxy}-N-[3-(1H-tetrazol-1-yl)phenyl]acetamide	
88	N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[[3-methyl-4-(1H-tetrazol-1-yl)phenyl]oxy]acetamide	
89	N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[[4-(1H-1,2,3-triazol-1-yl)phenyl]oxy]acetamide	
90	N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[[3-fluoro-4-(1H-tetrazol-1-yl)phenyl]oxy]acetamide	

Table 3

Entry	Name	Structure
91	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[2-fluoro-4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	
92	N-([4-chloro-3- (trifluoromethyl)phenyl]amino)carbonyl)- 3-(1H-tetrazol-1-yl)benzenesulfonamide	
93	N-([4-chloro-3- (trifluoromethyl)phenyl]amino)carbonyl)- N-methyl-3-(1H-tetrazol-1- yl)benzenesulfonamide	
94	N-[4-fluoro-3-(trifluoromethyl)phenyl]-2- [(4-pyridin-3-yl)phenyl]oxy}acetamide	
95	2-([4-[2,4-bis(methyloxy)pyrimidin-5- yl]phenyl]oxy)-N-[4-fluoro-3- (trifluoromethyl)phenyl]acetamide	
96	2-([4-[2,4-bis(methyloxy)pyrimidin-5- yl]phenyl]oxy)-N-[4-chloro-3- (trifluoromethyl)phenyl]acetamide	
97	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(4-pyridin-4-yl)phenyl]oxy}acetamide	

Table 3

Entry	Name	Structure
98	N-[4-chloro-3-(trifluoromethyl)phenyl]-N~2~-[3-(methoxy)-4-(1H-tetrazol-1-yl)phenyl]glycinamide	
99	N-[4-chloro-3-(trifluoromethyl)phenyl]-N~2~-[4-(methoxy)-3-(1H-tetrazol-1-yl)phenyl]glycinamide	
100	N-[4-chloro-3-(trifluoromethyl)phenyl]-N~2~-[4-(1H-tetrazol-1-yl)phenyl]glycinamide	
101	N-[4-chloro-3-(trifluoromethyl)phenyl]-2-(2,3,5,6-tetrafluoro-4-pyrimidin-5-ylphenyl)hydrazinecarboxamide	
102	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-{[4-(1H-tetrazol-1-yl)phenyl]methyl}urea	
103	N-[4-chloro-3-(trifluoromethyl)phenyl]-2-(4-pyrimidin-5-ylphenyl)hydrazinecarboxamide	
104	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[(3-pyridin-3-ylphenyl)methyl]urea	

Table 3

Entry	Name	Structure
105	N-[4-chloro-3-(trifluoromethyl)phenyl]-2-methyl-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}propanamide	
106	N-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[4-(1H-tetrazol-1-yl)phenyl]oxy}propanamide	
107	N-({4-[2,4-bis(methyloxy)pyrimidin-5-yl]phenyl}methyl)-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	
108	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-({3-[2-(methyloxy)pyrimidin-5-yl]phenyl}methyl)urea	
109	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-({3-[6-(methyloxy)pyridin-3-yl]phenyl}methyl)urea	
110	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-({4-[2-(methyloxy)pyrimidin-5-yl]phenyl}methyl)urea	
111	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-({4-[6-(methyloxy)pyridin-3-yl]phenyl}methyl)urea	

Table 3

Entry	Name	Structure
112	1,1-dimethylethyl 2-{4-[(2-{[4-chloro-3-(trifluoromethyl)phenyl]amino}-2-oxoethyl)oxy]phenyl}-1H-indole-1-carboxylate	
113	N-([4-chloro-3-(trifluoromethyl)phenyl]amino)carbonyl)-4-(1H-tetrazol-1-yl)benzenesulfonamide	
114	N-[4-chloro-3-(trifluoromethyl)phenyl]-N-2-~[3-(2H-tetrazol-5-yl)phenyl]glycinamide	
115	N-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[2,6-difluoro-4-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	
116	(3-pyridin-3-ylphenyl)methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	
117	(3-pyrimidin-5-ylphenyl)methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	
118	(3-pyridin-4-ylphenyl)methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	

Table 3








Entry	Name	Structure
119	N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[4-(1H-tetrazol-1-yl)phenyl]hydrazinecarboxamide	
120	N-[4-chloro-3-(trifluoromethyl)phenyl]-2-(4-pyridin-3-ylphenyl)hydrazinecarboxamide	
121	(4-pyridin-3-ylphenyl)methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	
122	(4-pyridin-4-ylphenyl)methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	
123	(4-pyrimidin-5-ylphenyl)methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	
124	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[(4-pyridin-4-ylphenyl)methyl]urea	
125	N-[4-chloro-3-(trifluoromethyl)phenyl]-2-(3-pyridin-3-ylphenyl)hydrazinecarboxamide	

Table 3








Entry	Name	Structure
126	N-[4-chloro-3-(trifluoromethyl)phenyl]-2-(3-pyrimidin-5-ylphenyl)hydrazinecarboxamide	
127	N-[5-chloro-2,4-bis(methoxy)phenyl]-N'-[(4-pyrimidin-5-ylphenyl)methyl]urea	
128	N-[5-chloro-2,4-bis(methoxy)phenyl]-N'-[(4-pyridin-3-ylphenyl)methyl]urea	
129	(4-pyrimidin-5-ylphenyl)methyl [5-chloro-2,4-bis(methoxy)phenyl]carbamate	
130	(4-pyridin-3-ylphenyl)methyl [5-chloro-2,4-bis(methoxy)phenyl]carbamate	
131	1-(4-pyridin-3-ylphenyl)ethyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	
132	1-(4-pyrimidin-5-ylphenyl)ethyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	

Table 3

Entry	Name	Structure
133	N-[5-chloro-2,4-bis(methoxy)phenyl]-N'-[(3-pyridin-3-ylphenyl)methyl]urea	
134	N-[5-chloro-2,4-bis(methoxy)phenyl]-N'-[(3-pyrimidin-5-ylphenyl)methyl]urea	
135	(3-pyridin-3-ylphenyl)methyl [5-chloro-2,4-bis(methoxy)phenyl]carbamate	
136	(3-pyrimidin-5-ylphenyl)methyl [5-chloro-2,4-bis(methoxy)phenyl]carbamate	
137	N-[4-chloro-3-(trifluoromethyl)phenyl]-2-methyl-2-(3-pyrimidin-5-ylphenyl)hydrazinecarboxamide	
138	N-[4-fluoro-3-(trifluoromethyl)phenyl]-N'-[(4-pyridin-3-ylphenyl)methyl]urea	
139	N-{[3-(6-aminopyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	

Table 3

Entry	Name	Structure
140	N-([4-(6-aminopyridin-3-yl)phenyl]methyl)-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	
141	N-([3-(2-aminopyrimidin-5-yl)phenyl]methyl)-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	
142	N-([4-(2-aminopyrimidin-5-yl)phenyl]methyl)-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	
143	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[1-(4-pyridin-3-ylphenyl)ethyl]urea	
144	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[1-(4-pyrimidin-5-ylphenyl)ethyl]urea	
145	N-[4-chloro-3-(trifluoromethyl)phenyl]-2-[[4-(1H-indol-2-yl)phenyl]oxy]acetamide	
146	N-[4-chloro-3-(trifluoromethyl)phenyl]-2-(isoquinolin-7-yloxy)acetamide	

Table 3

Entry	Name	Structure
147	N-[4-chloro-3-(trifluoromethyl)phenyl]-2-(4-pyridin-4-ylphenyl)hydrazinecarboxamide	
148	N-[4-chloro-3-(trifluoromethyl)phenyl]-2-(3-pyridin-4-ylphenyl)hydrazinecarboxamide	
149	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[(3-pyridin-4-ylphenyl)methyl]urea	
150	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[(3-quinoxalin-6-ylphenyl)methyl]urea	
151	methyl 3-amino-6-(3-{{{[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl]amino}methyl}phenyl)pyrazine-2-carboxylate	
152	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[(4-quinoxalin-6-ylphenyl)methyl]urea	
153	N-{[3-(2-amino-5-methylpyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	

Table 3

Entry	Name	Structure
154	methyl 3-amino-6-(4-([4-chloro-3-(trifluoromethyl)phenyl]amino)carbonyl)amino]methyl}phenyl)pyrazine-2-carboxylate	
155	[3-(1H-tetrazol-1-yl)phenyl]methyl [3-chloro-4-(methyloxy)phenyl]carbamate	
156	N-[3-chloro-4-(methyloxy)phenyl]-N'-{[3-(1H-tetrazol-1-yl)phenyl]methyl}urea	
157	N-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[4-(5-hydroxy-1H-tetrazol-1-yl)phenyl]oxy}acetamide	
158	N-{[3-(2-amino-5-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	
159	N-{[4-(2-amino-5-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	
160	N-{[3-(6-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	

Table 3

Entry	Name	Structure
161	N-{{4-(6-chloropyridin-3-yl)phenyl}methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	
162	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-{{4-(pyrimidin-2-yloxy)phenyl}methyl}urea	
163	N-({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)-3-(1H-tetrazol-1-yl)benzamide	
164	3-amino-6-(3-{{[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl}amino)methyl}phenyl)-N-[2-(dimethylamino)ethyl]pyrazine-2-carboxamide	
165	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-{{3-(6-fluoropyridin-3-yl)phenyl}methyl}urea	
166	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-({3-[2-(methyloxy)pyridin-3-yl]phenyl}methyl)urea	
167	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-{{4-(6-fluoropyridin-3-yl)phenyl}methyl}urea	

Table 3

Entry	Name	Structure
168	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-({4-[2-(methyloxy)pyridin-3-yl]phenyl}methyl)urea	
169	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-{[4-(6-methylpyridin-3-yl)phenyl]methyl}urea	
170	N-{[4-(2-amino-5-fluoropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	
171	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-{[3-(6-methylpyridin-3-yl)phenyl]methyl}urea	
172	N-{[4-(2-aminopyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	
173	N-{[3-(2-aminopyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	
174	[3-(6-methylpyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	

Table 3

Entry	Name	Structure
175	[3-(2-amino-5-fluoropyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	
176	[3-(2-aminopyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	
177	(3-pyrazin-2-ylphenyl)methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	
178	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-({3-[6-(hydroxymethyl)pyridin-3-yl]phenyl}methyl)urea	
179	N-{{3-(6-acetylpyridin-3-yl)phenyl}methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	
180	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-{{3-(6-cyanopyridin-3-yl)phenyl}methyl}urea	
181	1,1-dimethylethyl (3S)-3-(((3-amino-6-(3-(((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)pyrazin-2-yl)carbonyl)amino)piperidine-1-carboxylate	

Table 3

Entry	Name	Structure
182	3-amino-6-(3-{{{[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl]amino}methyl}phenyl)-N-[(3S)-piperidin-3-yl]pyrazine-2-carboxamide	
183	1,1-dimethylethyl (3S)-3-(((3-amino-6-(4-{{{[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl]amino}methyl}phenyl)pyrazin-2-yl)carbonyl)amino)piperidine-1-carboxylate	
184	3-amino-6-(4-{{{[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl]amino}methyl}phenyl)-N-[(3S)-piperidin-3-yl]pyrazine-2-carboxamide	
185	[3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	
186	N-{[3-(2-amino-5-fluoropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	
187	[6-(1H-tetrazol-1-yl)pyridin-2-yl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	

Table 3

Entry	Name	Structure
188	[3-(1H-benzimidazol-2-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	
189	[3-(6-amino-2-methylpyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	
190	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-((3-[5-(methylthio)pyridin-3-yl]phenyl)methyl)urea	
191	[4-(6-methylpyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	
192	[4-(2-amino-5-fluoropyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	
193	[4-(2-aminopyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	
194	(4-pyrazin-2-ylphenyl)methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	

Table 3

Entry	Name	Structure
195	[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	
196	[4-(6-amino-2-methylpyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	
197	[3-(1H-tetrazol-1-yl)phenyl]methyl 1,3-benzothiazol-2-ylcarbamate	
198	[3-(1H-tetrazol-1-yl)phenyl]methyl (5-bromopyridin-2-yl)carbamate	
199	(3-pyridin-3-ylphenyl)methyl (3,5-dimethylphenyl)carbamate	
200	(3-pyridin-3-ylphenyl)methyl [5-chloro-2-(methoxy)phenyl]carbamate	
201	[4-(1H-tetrazol-1-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	

Table 3

Entry	Name	Structure
202	(3-pyrimidin-5-ylphenyl)methyl [5-chloro-2-(methyloxy)phenyl]carbamate	
203	(4-pyrimidin-5-ylphenyl)methyl (3,4-dimethylphenyl)carbamate	
204	(3-pyridin-3-ylphenyl)methyl (3,4-dimethylphenyl)carbamate	
205	1,1-dimethylethyl 3-({[3-amino-6-(3-{{[[[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl]amino]methyl}phenyl)pyrazin-2-yl]carbonyl}amino)piperidine-1-carboxylate	
206	1,1-dimethylethyl 3-({[3-amino-6-(4-{{[[[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl]amino]methyl}phenyl)pyrazin-2-yl]carbonyl}amino)piperidine-1-carboxylate	
207	3-amino-6-(3-{{[[[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl]amino]methyl}phenyl)-N-piperidin-3-ylpyrazine-2-carboxamide	

Table 3

Entry	Name	Structure
208	3-amino-6-(4-(((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-N-piperidin-3-ylpyrazine-2-carboxamide	
209	1,1-dimethylethyl 4-{[3-amino-6-(3-(((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl]pyrazin-2-yl}carbonyl}piperazine-1-carboxylate	
210	1,1-dimethylethyl 4-{[3-amino-6-(4-(((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl]pyrazin-2-yl}carbonyl}piperazine-1-carboxylate	
211	N-((3-[5-amino-6-(piperazin-1-ylcarbonyl)pyrazin-2-yl]phenyl)methyl)-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	

Table 3

Entry	Name	Structure
212	N-({4-[5-amino-6-(piperazin-1-ylcarbonyl)pyrazin-2-yl]phenyl}methyl)-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	
213	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-{[3-(1H-pyrazol-4-yl)phenyl]methyl}urea	
214	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-{[4-(1H-pyrazol-4-yl)phenyl]methyl}urea	
215	[3-(2-piperazin-1-ylpyrimidin-5-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	
216	[4-(2-piperazin-1-ylpyrimidin-5-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	
217	N-{[3-(2-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	



Table 3

Entry	Name	Structure
218	N-{[4-(2-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	
219	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-{[3-(2-fluoropyridin-3-yl)phenyl]methyl}urea	
220	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-{[4-(2-fluoropyridin-3-yl)phenyl]methyl}urea	
221	[3-(1H-tetrazol-1-yl)phenyl]methyl [3-(trifluoromethyl)phenyl]carbamate	
222	[3-(1H-tetrazol-1-yl)phenyl]methyl [6-(trifluoromethyl)pyridin-2-yl]carbamate	
223	[3-(1H-tetrazol-1-yl)phenyl]methyl [4-(trifluoromethyl)pyridin-2-yl]carbamate	
224	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-({3-[5-(methylthio)pyridin-2-yl]phenyl}methyl)urea	

Table 3

Entry	Name	Structure
225	[3-(2,6-dimethylpyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	
226	{3-[5-(methyloxy)pyridin-3-yl]phenyl}methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	
227	2,3'-bipyridin-6-ylmethyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	
228	(6-pyrimidin-5-ylpyridin-2-yl)methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	
229	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[(3-isoquinolin-4-ylphenyl)methyl]urea	
230	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[(4-isoquinolin-4-ylphenyl)methyl]urea	
231	[6-(1H-tetrazol-1-yl)pyridin-2-yl]methyl [4-(trifluoromethyl)pyridin-2-yl]carbamate	

Table 3

Entry	Name	Structure
232	[3-(1H-pyrazol-4-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	
233	[4-(1H-pyrazol-4-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	

28. A pharmaceutical composition comprising the compound according to any one of claims 1 - 27 and a pharmaceutically acceptable carrier.

29. A metabolite of the compound or the pharmaceutical composition according to any one of claims 1 - 28.

30. A method for modulating the *in-vivo* activity of a kinase, the method comprising administering to a subject an effective amount of the compound according to any of claims 1 - 27 or a compound selected from N-naphthalen-1-yl-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(phenyloxy)phenyl]-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(3,4-dimethylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,3-dimethylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,4-dimethylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,5-dimethylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(3,5-dimethylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,6-dimethylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, 2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}-N-(2,4,6-trimethylphenyl)acetamide, N-(2-ethylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(4-ethylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,6-diethylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[2-(methyloxy)phenyl]-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[2-(ethyloxy)phenyl]-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[3-(ethyloxy)phenyl]-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[2,4-bis(methyloxy)phenyl]-2-{{[3-(1H-tetrazol-1-

yl)phenyl]oxy} acetamide, N-[4-(dimethylamino)phenyl]-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(2,3-dichlorophenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(4-chloro-3-methylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(4-bromophenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(2-fluorophenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(4-fluorophenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, 2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}-N-[2-(trifluoromethyl)phenyl]acetamide, 2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}-N-[3-(trifluoromethyl)phenyl]acetamide, methyl 4-[[[3-(1H-tetrazol-1-yl)phenyl]oxy]acetyl]amino]benzoate, ethyl 4-[[[3-(1H-tetrazol-1-yl)phenyl]oxy]acetyl]amino]benzoate, 3-[[[3-(1H-tetrazol-1-yl)phenyl]oxy]acetyl]amino]benzoic acid, N-[3-(methyloxy)phenyl]-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-[4-(methyloxy)phenyl]-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-[2-chloro-5-(trifluoromethyl)phenyl]-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-{{[3-(4H-1,2,4-triazol-4-yl)phenyl]oxy}acetamide, N-(4-chlorophenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(4-aminophenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, and N-(4-acetylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide.

31. The method according to claim 30, wherein the kinase is c-Kit.

32. The method according to claim 31, wherein modulating the *in vivo* activity of c-Kit comprises inhibition of c-Kit.

33. A method of treating diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities, the method comprising administering, to a mammal in need thereof, a therapeutically effective amount of the compound or the pharmaceutical composition as described in any one of claims 1-28 or a compound, or a pharmaceutical composition comprising said compound, selected from N-naphthalen-1-yl-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-[4-(phenyloxy)phenyl]-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(3,4-dimethylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(2,3-dimethylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(2,4-dimethylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(2,5-dimethylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(3,5-dimethylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(2,6-dimethylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, 2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}-N-(2,4,6-trimethylphenyl)acetamide, N-(2-ethylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}

acetamide, N-(4-ethylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,6-diethylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[2-(methyloxy)phenyl]-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[2-(ethyloxy) phenyl]-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[3-(ethyloxy)phenyl]-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[2,4-bis(methyl-oxy)phenyl]-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(dimethylamino)-phenyl]-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,3-dichlorophenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(4-chloro-3-methylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(4-bromophenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2-fluorophenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(4-fluorophenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, 2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}-N-[2-(trifluoromethyl)phenyl] acetamide, 2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}-N-[3-(trifluoromethyl)phenyl] acetamide, methyl 4-[[{{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetyl]amino] benzoate, ethyl 4-[[{{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetyl]amino] benzoate, 3-[[{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetyl] amino] benzoic acid, N-[3-(methyloxy)phenyl]-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(methyloxy)phenyl]-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[2-chloro-5-(trifluoromethyl)phenyl]-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-{{[3-(4H-1,2,4-triazol-4-yl)phenyl]oxy} acetamide, N-(4-chlorophenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(4-aminophenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, and N-(4-acetylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide.

34. A method of screening for modulators of c-Kit, the method comprising combining the compound according to any one of claims 1 -27 or a compound selected from N-naphthalen-1-yl-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(phenoxy)phenyl]-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(3,4-dimethylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,3-dimethylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,4-dimethylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,5-dimethylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(3,5-dimethylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,6-dimethylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, 2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}-N-(2,4,6-trimethylphenyl)acetamide, N-(2-ethylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(4-ethylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,6-diethylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[2-

(methyloxy)phenyl]-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[2-(ethyloxy)phenyl]-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-[3-(ethyloxy)phenyl]-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[2,4-bis(methyloxy)phenyl]-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(dimethylamino)phenyl]-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(2,3-dichlorophenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(4-chloro-3-methylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(4-bromophenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(2-fluorophenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(4-fluorophenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, 2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}-N-[2-(trifluoromethyl)phenyl] acetamide, 2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}-N-[3-(trifluoromethyl)phenyl] acetamide, methyl 4-[[{{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetyl]amino] benzoate, ethyl 4-[[{{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetyl]amino] benzoate, 3-[[{{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetyl]amino] benzoic acid, N-[3-(methyloxy)phenyl]-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(methyloxy)phenyl]-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[2-chloro-5-(trifluoromethyl)phenyl]-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-{{[3-(4H-1,2,4-triazol-4-yl)phenyl]oxy} acetamide, N-(4-chlorophenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(4-aminophenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, and N-(4-acetylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, and at least one candidate agent and determining the effect of the candidate agent on c-Kit activity.

35. A method of inhibiting proliferative activity in a cell, the method comprising administering an effective amount of a composition comprising the compound according any one of claims 1 - 27 or a compound selected from N-naphthalen-1-yl-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(phenyloxy)phenyl] -2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(3,4-dimethylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,3-dimethylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,4-dimethylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,5-dimethylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-(3,5-dimethylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,6-dimethyl-phenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, 2-{{[3-(1H-tetrazol-1-yl)phenyl] oxy}-N-(2,4,6-trimethylphenyl)acetamide, N-(2-ethylphenyl)-2-{{[3-(1H-tetrazol-1-yl) phenyl]oxy} acetamide, N-(4-ethylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,6-diethylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide, N-[2-(methyloxy)phenyl]-

2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[2-(ethyloxy) phenyl]-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[3-(ethyloxy)phenyl]-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[2,4-bis(methyloxy)phenyl]-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(dimethylamino)phenyl]-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2,3-dichlorophenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(4-chloro-3-methylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(4-bromophenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(2-fluorophenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(4-fluorophenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, 2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}-N-[2-(trifluoromethyl)phenyl] acetamide, 2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy}-N-[3-(trifluoromethyl)phenyl] acetamide, methyl 4-[[[3-(1H-tetrazol-1-yl)phenyl]oxy]acetyl]amino] benzoate, ethyl 4-[[[3-(1H-tetrazol-1-yl)phenyl]oxy]acetyl]amino] benzoate, 3-[[[3-(1H-tetrazol-1-yl)phenyl]oxy]acetyl]amino] benzoic acid, N-[3-(methyloxy)phenyl]-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-(methyloxy)phenyl]-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[2-chloro-5-(trifluoromethyl)phenyl]-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-{{[3-(4H-1,2,4-triazol-4-yl)phenyl]oxy} acetamide, N-(4-chlorophenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, N-(4-aminophenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, and N-(4-acetylphenyl)-2-{{[3-(1H-tetrazol-1-yl)phenyl]oxy} acetamide, to a cell or a plurality of cells.